{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["bortezomib"],["lenalidomide"]],"indication":"high-risk untreated follicular lymphoma","name":"ECOG-ACRIN E2408","nct_id":"NCT01216683","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ecog-acrin-e2408-nct01216683. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Arm A (induction): Patients receive rituximab intravenously (IV) on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nArm D (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.","label":"Arm A then Arm D (Induction with Bendamustine + Rituximab; Continuation with Rituximab)","type":"EXPERIMENTAL"},{"description":"Arm B (induction): Patients receive rituximab IV on day 1; bortezomib IV on days 1, 4, 8, and 11; and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nArm E (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab as in arm D.","label":"Arm B then Arm E (Induction with Bendamustine + Rituximab + Bortezomib; Continuation with Rituximab)","type":"EXPERIMENTAL"},{"description":"Arm C (induction): Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nArm F (continuation): Immediately after completing induction therapy, patients who have stable disease or better at time of post-induction restaging receive oral lenalidomide on days 1-21. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, these patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.","label":"Arm C then Arm F (Induction with Bendamustine+Rituximab; Continuation with Lenalidomide + Rituximab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2019-12-02","type":"ACTUAL"},"conditions":["Lymphoma"],"enrollment":{"count":289,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"rituximab","otherNames":["IDEC-C2B8","Chimeric anti-CD20 monoclonal antibody","Rituxan"],"type":"BIOLOGICAL"},{"name":"Bendamustin","otherNames":["Bendamustine hydrochloride","CEP-18083","TREANDA"],"type":"DRUG"},{"name":"bortezomib","otherNames":["MLN341","LDP-341","Velcade®","PS-341"],"type":"DRUG"},{"name":"lenalidomide","otherNames":["IMiD compound CC-5013","Revlimid®"],"type":"DRUG"}],"last_update":"2023-06-29","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2019-12-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Remission (CR) Rate","timeFrame":"Assessed every 4 weeks during induction treatment and every 8 weeks during continuation treatment, up to 2 years"},{"measure":"1-year Post-induction Disease-free Survival (DFS) Rate","timeFrame":"Assessed at 1 year post-induction, approximately 1.5 years"}],"references":[{"citation":"Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl BS. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clin Cancer Res. 2020 Sep 1;26(17):4468-4477. doi: 10.1158/1078-0432.CCR-20-1345. Epub 2020 Jun 12.","pmid":"32532790","type":"RESULT"}],"start_date":{"date":"2011-02-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma","url":"https://clinicaltrials.gov/study/NCT01216683"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ecog-acrin-e2408-nct01216683"}